Literature DB >> 19389506

AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma.

Dorit E Zilberman1, Yoram Cohen, Ninette Amariglio, Edward Fridman, Jacob Ramon, Gideon Rechavi.   

Abstract

The PI3K/AKT pathway is frequently activated in human cancer. Recently, a G to A point mutation (E17K) was found in the pleckstrin homology domain of AKT1. We aimed to explore this mutation in cases of urothelial carcinoma. Using chip-based matrix-assisted laser desorption-time-of-flight (MALDI-TOF) mass spectrometer, AKT1 E17K mutation was searched in 26 total RNA samples obtained from 26 patients known to have urothelial carcinoma. Mutation was found in one out of 26 (3.8%) patients - a 46 year old female with a low grade transitional cell carcinoma located to the lamina propria (Ta disease). Our finding is in line with previous studies showing AKT1 E17K mutation to be rare. Yet, further studies are required to determine whether this mutation is indeed related to less aggressive disease and carries better prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389506     DOI: 10.1016/j.cancergencyto.2009.01.009

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Akt1 deletion prevents lung tumorigenesis by mutant K-ras.

Authors:  M C Hollander; C R Maier; E A Hobbs; A R Ashmore; R I Linnoila; P A Dennis
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

Review 2.  Regulation of Akt signaling activation by ubiquitination.

Authors:  Wei-Lei Yang; Ching-Yuan Wu; Juan Wu; Hui-Kuan Lin
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

3.  E17K substitution in AKT1 in prostate cancer.

Authors:  J L Boormans; H Korsten; A C J Ziel-van der Made; G J L H van Leenders; P C M S Verhagen; J Trapman
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

4.  Effects of AKT1 E17K mutation hotspots on the biological behavior of breast cancer cells.

Authors:  Wanwen Wu; Ying Chen; Lan Huang; Wenjian Li; Changli Tao; Han Shen
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

Review 5.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.

Authors:  Motoyasu Saji; Matthew D Ringel
Journal:  Mol Cell Endocrinol       Date:  2009-11-06       Impact factor: 4.102

6.  Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain.

Authors:  Ambuj Kumar; Rituraj Purohit
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

7.  K63-linked ubiquitination in kinase activation and cancer.

Authors:  Guocan Wang; Yuan Gao; Liren Li; Guoxiang Jin; Zhen Cai; Jui-I Chao; Hui-Kuan Lin
Journal:  Front Oncol       Date:  2012-01-31       Impact factor: 6.244

8.  Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

Authors:  Yi Yu; Ronald E Savage; Sudharshan Eathiraj; Justin Meade; Michael J Wick; Terence Hall; Giovanni Abbadessa; Brian Schwartz
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

9.  Mutant AKT1-E17K is oncogenic in lung epithelial cells.

Authors:  Carmela De Marco; Donatella Malanga; Nicola Rinaldo; Fernanda De Vita; Marianna Scrima; Sara Lovisa; Linda Fabris; Maria Vincenza Carriero; Renato Franco; Antonia Rizzuto; Gustavo Baldassarre; Giuseppe Viglietto
Journal:  Oncotarget       Date:  2015-11-24

10.  Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.

Authors:  Maria L Mancini; Evan C Lien; Alex Toker
Journal:  Oncotarget       Date:  2016-04-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.